A consortium of life sciences investors is set to begin exclusive talks to buy a £500m portfolio of healthcare assets from the Woodford Equity Income fund (WEIF).
WG Partners has assembled a group of backers, including pharmaceuticals investor Ricanto, all set to buy around 15 positions held in WEIF, according to Sky News. Among the companies included in the proposition are Oxford Nanopore, 4D Pharma, Mereo BioPharma Group, Rutherford Health, Immunocore, Kymab, Arix Bioscience and Verseon. 2019: An appalling year for Woodford Notably, it excludes the fund's second-largest unquoted healthcare holding, BenevolentAI. Benevolent AI saw its valuation halve in September on the back of investment from Singapore wealth fund Temasek, which took a ...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
